New applications of disease genetics and pharmacogenetics to drug development
Highlights • A variable polyT variation within TOMM40 was associated with MCI-AD. • TOMM40 genotypes are 97% informative for estimating age of onset risk. • TOMMORROW is a Phase III delay of onset of MCI-AD in 65–83 year olds. • Pioglitazone has a large safety experience and used in TOMMORROW. • TOM...
Gespeichert in:
| Veröffentlicht in: | Current opinion in pharmacology 2014-02, Vol.14, p.81-89 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 89 |
|---|---|
| container_issue | |
| container_start_page | 81 |
| container_title | Current opinion in pharmacology |
| container_volume | 14 |
| creator | Roses, Allen D Saunders, Ann M Lutz, Michael W Zhang, Nanyin Hariri, Ahmad R Asin, Karen E Crenshaw, Donna G Budur, Kumar Burns, Daniel K Brannan, Stephen K |
| description | Highlights • A variable polyT variation within TOMM40 was associated with MCI-AD. • TOMM40 genotypes are 97% informative for estimating age of onset risk. • TOMMORROW is a Phase III delay of onset of MCI-AD in 65–83 year olds. • Pioglitazone has a large safety experience and used in TOMMORROW. • TOMM40, APOE and age are used to stratify the aged normal population. |
| doi_str_mv | 10.1016/j.coph.2013.12.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1524404061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1471489213002348</els_id><sourcerecordid>1514425350</sourcerecordid><originalsourceid>FETCH-LOGICAL-c554t-33ffde76d7960eaa5a96c1440f23337c43d6e46cd65951be60c8a1f882393cb83</originalsourceid><addsrcrecordid>eNqNkUtP3TAQha0KVCjtH-gCZcnmph6_kkhVJYSgrcRj0XZt-doT8CWJg52A-Pd1dIEFC8TKI-ucM6PvEPIVaAkU1LdNacN4UzIKvARWUso-kH0QFaxEU_Gd57lu2B75lNKGUpCcVx_JHhNSyRyxTy4u8aEw49h5ayYfhlSEtnA-oUlYXOOAk7epMIMrxhsTe2PDy-cUChfn68LhPXZh7HGYPpPd1nQJvzy9B-Tf2enfk1-r86ufv0-Oz1dWSjGtOG9bh5VyVaMoGiNNoywIQVvG84FWcKdQKOuUbCSsUVFbG2jrmvGG23XND8jRNneM4W7GNOneJ4tdZwYMc9IgWU4TVME7pHkxk1zSLGVbqY0hpYitHqPvTXzUQPVCXG_0QlwvxDUwnYln0-FT_rzu0b1YnhFnwfetADOQe49RJ-txsOh8RDtpF_zb-T9e2W3nh9xWd4uPmDZhjkNGrUGnbNB_ls6XyoEvblHz_23vpiM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1514425350</pqid></control><display><type>article</type><title>New applications of disease genetics and pharmacogenetics to drug development</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Roses, Allen D ; Saunders, Ann M ; Lutz, Michael W ; Zhang, Nanyin ; Hariri, Ahmad R ; Asin, Karen E ; Crenshaw, Donna G ; Budur, Kumar ; Burns, Daniel K ; Brannan, Stephen K</creator><creatorcontrib>Roses, Allen D ; Saunders, Ann M ; Lutz, Michael W ; Zhang, Nanyin ; Hariri, Ahmad R ; Asin, Karen E ; Crenshaw, Donna G ; Budur, Kumar ; Burns, Daniel K ; Brannan, Stephen K</creatorcontrib><description>Highlights • A variable polyT variation within TOMM40 was associated with MCI-AD. • TOMM40 genotypes are 97% informative for estimating age of onset risk. • TOMMORROW is a Phase III delay of onset of MCI-AD in 65–83 year olds. • Pioglitazone has a large safety experience and used in TOMMORROW. • TOMM40, APOE and age are used to stratify the aged normal population.</description><identifier>ISSN: 1471-4892</identifier><identifier>EISSN: 1471-4973</identifier><identifier>DOI: 10.1016/j.coph.2013.12.002</identifier><identifier>PMID: 24565016</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aged ; Aged, 80 and over ; Algorithms ; Alzheimer Disease - genetics ; Alzheimer Disease - prevention & control ; Animals ; Brain - pathology ; Clinical Trials, Phase III as Topic - methods ; Cognitive Dysfunction - genetics ; Cognitive Dysfunction - prevention & control ; Drug Design ; Genotype ; Humans ; Internal Medicine ; Medical Education ; Pharmacogenetics ; Thiazolidinediones - administration & dosage ; Thiazolidinediones - pharmacology</subject><ispartof>Current opinion in pharmacology, 2014-02, Vol.14, p.81-89</ispartof><rights>The Authors</rights><rights>2013 The Authors</rights><rights>Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c554t-33ffde76d7960eaa5a96c1440f23337c43d6e46cd65951be60c8a1f882393cb83</citedby><cites>FETCH-LOGICAL-c554t-33ffde76d7960eaa5a96c1440f23337c43d6e46cd65951be60c8a1f882393cb83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1471489213002348$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24565016$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roses, Allen D</creatorcontrib><creatorcontrib>Saunders, Ann M</creatorcontrib><creatorcontrib>Lutz, Michael W</creatorcontrib><creatorcontrib>Zhang, Nanyin</creatorcontrib><creatorcontrib>Hariri, Ahmad R</creatorcontrib><creatorcontrib>Asin, Karen E</creatorcontrib><creatorcontrib>Crenshaw, Donna G</creatorcontrib><creatorcontrib>Budur, Kumar</creatorcontrib><creatorcontrib>Burns, Daniel K</creatorcontrib><creatorcontrib>Brannan, Stephen K</creatorcontrib><title>New applications of disease genetics and pharmacogenetics to drug development</title><title>Current opinion in pharmacology</title><addtitle>Curr Opin Pharmacol</addtitle><description>Highlights • A variable polyT variation within TOMM40 was associated with MCI-AD. • TOMM40 genotypes are 97% informative for estimating age of onset risk. • TOMMORROW is a Phase III delay of onset of MCI-AD in 65–83 year olds. • Pioglitazone has a large safety experience and used in TOMMORROW. • TOMM40, APOE and age are used to stratify the aged normal population.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Algorithms</subject><subject>Alzheimer Disease - genetics</subject><subject>Alzheimer Disease - prevention & control</subject><subject>Animals</subject><subject>Brain - pathology</subject><subject>Clinical Trials, Phase III as Topic - methods</subject><subject>Cognitive Dysfunction - genetics</subject><subject>Cognitive Dysfunction - prevention & control</subject><subject>Drug Design</subject><subject>Genotype</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical Education</subject><subject>Pharmacogenetics</subject><subject>Thiazolidinediones - administration & dosage</subject><subject>Thiazolidinediones - pharmacology</subject><issn>1471-4892</issn><issn>1471-4973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtP3TAQha0KVCjtH-gCZcnmph6_kkhVJYSgrcRj0XZt-doT8CWJg52A-Pd1dIEFC8TKI-ucM6PvEPIVaAkU1LdNacN4UzIKvARWUso-kH0QFaxEU_Gd57lu2B75lNKGUpCcVx_JHhNSyRyxTy4u8aEw49h5ayYfhlSEtnA-oUlYXOOAk7epMIMrxhsTe2PDy-cUChfn68LhPXZh7HGYPpPd1nQJvzy9B-Tf2enfk1-r86ufv0-Oz1dWSjGtOG9bh5VyVaMoGiNNoywIQVvG84FWcKdQKOuUbCSsUVFbG2jrmvGG23XND8jRNneM4W7GNOneJ4tdZwYMc9IgWU4TVME7pHkxk1zSLGVbqY0hpYitHqPvTXzUQPVCXG_0QlwvxDUwnYln0-FT_rzu0b1YnhFnwfetADOQe49RJ-txsOh8RDtpF_zb-T9e2W3nh9xWd4uPmDZhjkNGrUGnbNB_ls6XyoEvblHz_23vpiM</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>Roses, Allen D</creator><creator>Saunders, Ann M</creator><creator>Lutz, Michael W</creator><creator>Zhang, Nanyin</creator><creator>Hariri, Ahmad R</creator><creator>Asin, Karen E</creator><creator>Crenshaw, Donna G</creator><creator>Budur, Kumar</creator><creator>Burns, Daniel K</creator><creator>Brannan, Stephen K</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20140201</creationdate><title>New applications of disease genetics and pharmacogenetics to drug development</title><author>Roses, Allen D ; Saunders, Ann M ; Lutz, Michael W ; Zhang, Nanyin ; Hariri, Ahmad R ; Asin, Karen E ; Crenshaw, Donna G ; Budur, Kumar ; Burns, Daniel K ; Brannan, Stephen K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c554t-33ffde76d7960eaa5a96c1440f23337c43d6e46cd65951be60c8a1f882393cb83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Algorithms</topic><topic>Alzheimer Disease - genetics</topic><topic>Alzheimer Disease - prevention & control</topic><topic>Animals</topic><topic>Brain - pathology</topic><topic>Clinical Trials, Phase III as Topic - methods</topic><topic>Cognitive Dysfunction - genetics</topic><topic>Cognitive Dysfunction - prevention & control</topic><topic>Drug Design</topic><topic>Genotype</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical Education</topic><topic>Pharmacogenetics</topic><topic>Thiazolidinediones - administration & dosage</topic><topic>Thiazolidinediones - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roses, Allen D</creatorcontrib><creatorcontrib>Saunders, Ann M</creatorcontrib><creatorcontrib>Lutz, Michael W</creatorcontrib><creatorcontrib>Zhang, Nanyin</creatorcontrib><creatorcontrib>Hariri, Ahmad R</creatorcontrib><creatorcontrib>Asin, Karen E</creatorcontrib><creatorcontrib>Crenshaw, Donna G</creatorcontrib><creatorcontrib>Budur, Kumar</creatorcontrib><creatorcontrib>Burns, Daniel K</creatorcontrib><creatorcontrib>Brannan, Stephen K</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Current opinion in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roses, Allen D</au><au>Saunders, Ann M</au><au>Lutz, Michael W</au><au>Zhang, Nanyin</au><au>Hariri, Ahmad R</au><au>Asin, Karen E</au><au>Crenshaw, Donna G</au><au>Budur, Kumar</au><au>Burns, Daniel K</au><au>Brannan, Stephen K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New applications of disease genetics and pharmacogenetics to drug development</atitle><jtitle>Current opinion in pharmacology</jtitle><addtitle>Curr Opin Pharmacol</addtitle><date>2014-02-01</date><risdate>2014</risdate><volume>14</volume><spage>81</spage><epage>89</epage><pages>81-89</pages><issn>1471-4892</issn><eissn>1471-4973</eissn><abstract>Highlights • A variable polyT variation within TOMM40 was associated with MCI-AD. • TOMM40 genotypes are 97% informative for estimating age of onset risk. • TOMMORROW is a Phase III delay of onset of MCI-AD in 65–83 year olds. • Pioglitazone has a large safety experience and used in TOMMORROW. • TOMM40, APOE and age are used to stratify the aged normal population.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24565016</pmid><doi>10.1016/j.coph.2013.12.002</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-4892 |
| ispartof | Current opinion in pharmacology, 2014-02, Vol.14, p.81-89 |
| issn | 1471-4892 1471-4973 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1524404061 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Aged, 80 and over Algorithms Alzheimer Disease - genetics Alzheimer Disease - prevention & control Animals Brain - pathology Clinical Trials, Phase III as Topic - methods Cognitive Dysfunction - genetics Cognitive Dysfunction - prevention & control Drug Design Genotype Humans Internal Medicine Medical Education Pharmacogenetics Thiazolidinediones - administration & dosage Thiazolidinediones - pharmacology |
| title | New applications of disease genetics and pharmacogenetics to drug development |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A00%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20applications%20of%20disease%20genetics%20and%20pharmacogenetics%20to%20drug%20development&rft.jtitle=Current%20opinion%20in%20pharmacology&rft.au=Roses,%20Allen%20D&rft.date=2014-02-01&rft.volume=14&rft.spage=81&rft.epage=89&rft.pages=81-89&rft.issn=1471-4892&rft.eissn=1471-4973&rft_id=info:doi/10.1016/j.coph.2013.12.002&rft_dat=%3Cproquest_cross%3E1514425350%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1514425350&rft_id=info:pmid/24565016&rft_els_id=S1471489213002348&rfr_iscdi=true |